Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manuel Penalver

Gynecologic Oncology Coral Gables, FL Medical Doctor

NPI 1821095829 CMS profile 127517

5000 University Dr, Suite 3300, Coral Gables, FL 33146

Open in the dashboard

General payments

$5,382

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manuel Penalver of Coral Gables, FL is reported in the CMS Open Payments database as having received $5,382 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $185 3
2024 General $1,230 19
2023 General $2,452 26
2022 General $864 14
2021 General $189 8
2020 General $99 5
2019 General $365 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manuel Penalver
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Manuel Penalver were reported at $185. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Manuel Penalver Gynecologic Oncology median Middle half National median
2019 $365 $287 $113–$1,548 $163
2020 $99 $223 $59–$2,164 $114
2021 $189 $193 $68–$1,139 $132
2022 $864 $252 $90–$1,151 $149
2023 $2,452 $281 $102–$1,419 $160
2024 $1,230 $308 $108–$1,502 $164
2025 $185 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $4,092 56 payments
  2. AbbVie, Inc. $321 16 payments
  3. Davol Inc. $305 6 payments
  4. Organogenesis Inc. $132 1 payment
  5. Pacira Pharmaceuticals Incorporated $122 1 payment
  6. Ethicon US, LLC $107 1 payment
  7. Merck Sharp & Dohme Corporation $49 3 payments
  8. Medtronic Vascular, Inc. $44 1 payment
  9. Hologic, LLC $43 2 payments
  10. GlaxoSmithKline, LLC. $42 2 payments
  11. Other $126 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,589 91 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $500 1 payment
  3. Education $203 2 payments
  4. Gift $91 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $3,592 55 payments
  2. DA VINCI SP $500 1 payment
  3. LO LOESTRIN FE $220 10 payments
  4. ARISTA AH FlexiTip $144 1 payment
  5. CYGNUS MATRIX $132 1 payment
  6. Exparel $122 1 payment
  7. SURGICEL NU-KNIT $107 1 payment
  8. Orilissa $63 4 payments
  9. ZEJULA $59 3 payments
  10. KEYTRUDA $49 3 payments
  11. Other $501 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

341

Median for Obstetrics & Gynecology: 65

Drug cost

$24,874

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

27%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 25 $12,531
Estradiol Generic 172 $9,576
Alclometasone Dipropionate Generic 47 $1,694
Progesterone Progesterone, Micronized Brand 12 $666
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 55 $222
Ciprofloxacin Hcl Generic 19 $136
Lorazepam Generic 11 $48

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$30,810

Medicare's payments for the services billed

Medicare patients

99

Average age 72

Services billed

183

99 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Cancer 34%
Diabetes 31%
Osteoporosis 27%
Chronic kidney disease 25%
Depression 25%
Ischemic heart disease 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record